Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03720548 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3372993 in Healthy Participants and Participants With Alzheimer's Disease (AD)
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT03720548 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 36 participants.
The verdict
NCT03720548, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the safety and tolerability of LY3372993 in healthy participants and participants with AD. The study will also investigate how much LY3372993 gets into the bloodstream and test the effects of LY3372993 in participants with AD. The study has two parts: * Part A - Healthy participants will receive LY3372993 or placebo. Part A will last up to 17 weeks; * Part B - Participants with AD will receive LY3372993 or placebo. Part B will last about 317 days.
Interventions
- DRUG Placebo
- DRUG LY3372993
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2018-11-05 |
| Est. Completion | 2019-05-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03720548
The ClinicalTrials.gov registry entry for NCT03720548 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03720548 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03720548 about?
NCT03720548 is a clinical study titled "A Study of LY3372993 in Healthy Participants and Participants With Alzheimer's Disease (AD)". The main purpose of this study is to evaluate the safety and tolerability of LY3372993 in healthy participants and participants with AD. The study will also investigate how much LY3372993 gets into the bloodstream and test the effects of LY3372993 in participants with AD. The study has two parts: ...
What is the current status of trial NCT03720548?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2018-11-05. Estimated completion is 2019-05-14.
What interventions are being tested in trial NCT03720548?
The interventions under investigation include: Placebo (DRUG), LY3372993 (DRUG).
Who is sponsoring clinical trial NCT03720548?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.